CA-DIVERSIFIED-NANO
28.9.2018 14:52:06 CEST | Business Wire | Press release
Diversified Nano Solutions Corp launches revolutionary smartINK™ solutions to deliver the next generation of functional security printing to brand owners in any industry, institutions and individuals.
For the first time functional content printing and total security are delivered simultaneously and cost effectively by integrating copy-proof, unique and customer-specific smartQR™ biomarkers (watch video ) with the whole spectrum of digital inks.
Breakthrough smartINK ™ provides print and instant product identity and location tracking, at unbelievably low cost, on-the-spot, anywhere, anytime, by anyone.
Counterfeiting and illicit trade are pervasive in nearly every industry sector, harming consumers and brand owners, while costing the global economy over 1 trillion dollars annually.
Preservation of product and information integrity is increasingly important as sophisticated counterfeiting efforts easily defeat existing anti-counterfeit technologies.
smartINK™ makes it fun and easy to verify item integrity while establishing trust and defending item value. The smartINK™ solution scales easily, so individual brand owners and large enterprises alike can grow market share and successfully eliminate illicit trade and counterfeiting. Unbelievably low implementation costs enable fast payback and rapid deployment of secure mobile authentication and tracking worldwide.
As an expansion beyond digital print, DNSC is powering INKcrypt® smartQR™ available at www.goinkcrypt.com . FDA-compliant INKcrypt® smartQR™ enables tagging and marking of any physical object with traces of custom biomarkers using a variety of methods – including spray, brush, roll, flexo, offset and more.
Contact https://inkcryptink.com/ContactUs.aspx for details and to coordinate implementation of your smartINK™ and INKcrypt® smartQR™ solution.
smartINK™ solutions are compatible with inkjet platforms offered by Canon®, Screen®, Epson®, Ricoh®, HP®, FujiFilm®, Xerox®, Kyocera®, Konica Minolta® and more. Visit booth 829 at PRINT 18 September 30-October 2, 2018, in Chicago.
About DNSC
Diversified Nano Solutions Corporation (DNSC) , based in San Diego, California, specializes in developing, manufacturing and marketing high-performance inkjet inks and revolutionary, industry-unique smartINK™ solutions. Utilizing customer-specific INKcrypt® xDNA biomarker technology, smartINK™ provides total product & document security, proof of identity and worldwide tracking, anytime anywhere, at incredibly low cost. smartINK™ combines INKcrypt® xDNA™ biomarkers, the power of the internet and DNSC’s extensive product line of inks including CMYK , MICR (Magnetic Ink Character Recognition), invisible UV fluorescent / IR absorbing , spot and custom formulations .
Accessories and Security
DNSC supports its ink offerings with accessories to facilitate and aid x-nano™ ink use and smartINK™ solutions. These include specialty substrates, smartQR™ biomarker authentication testers, UV display lights, INKVERSE ™ “Infinite Ink Infuser” – a revolutionary and cost-effective way to adopt and deliver digital inks to existing and new inkjet systems via a continuous delivery ink supply system, and TransChrome ™ – an invisible color image generator to transform visible CMYK into invisible UV fluorescent red, green, blue, and white (RGBW) output, and more.
DNSC is presenting smartINK™ solutions, INKcrypt® smartQR™ and its line of black & color, magnetic, invisible, special effect, and security inks for the world’s leading inkjet print systems in the desktop, commercial and industrial inkjet space.
Visit us at booth 829 and discover the future of digital ink: functional, secure, trackable, differentiating!
View source version on businesswire.com: https://www.businesswire.com/news/home/20180928005061/en/
Contact:
For more information: Diversified Nano Solutions Corporation Linda Meyers US Headquarters: +1.858.924.1005 EMEA: +41.41 874 08 50 info@diversifiednano.com www.diversifiednano.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom